Scalper1 News
Leerink Partners upgraded French pharma giant Sanofi (SNY) to outperform from market perform Tuesday, citing foreign-exchange tailwinds and the promising cholesterol-fighting drug news over the weekend. Analyst Seamus Fernandez wrote that some of the problems that plagued the company last fall — notably weak diabetes guidance and the loss of the CEO, who still hasn’t been replaced — are now resolved or priced into the stock. He also wrote that Scalper1 News
Scalper1 News